Fortis Healthcare FY25 Annual Earnings Summary
4 quarters covered · ₹7,782 Cr revenue · ₹809 Cr PAT · 20.4% average EBITDA margin.
Quarter-by-quarter progression
Management promises made during the year
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
Q1 FY25Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
Q1 FY25Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
Q1 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q2 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q2 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q3 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q4 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q4 FY25Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
Q4 FY25Risks flagged during the year
Increase in scheme business (CGHS/ECHS) and higher share of lower-margin specialties (ortho, onco) compressed hospital EBITDA margins by ~2% in Q1.
Q1 FY25 · mediumDiagnostics revenue remained flat YoY, with margins declining due to rebranding costs and government provisions; recovery may take longer than expected.
Q1 FY25 · mediumLegal costs related to the Daiichi litigation are expected to remain high this year, with potential appeals adding uncertainty.
Q2 FY25 · mediumAgilus revenue grew only 3.4% YoY, trailing peers, due to brand transition impact and low-value PPP business decline. Recovery to double-digit growth is uncertain.
Q2 FY25 · mediumNew bed additions at Manesar and other facilities are expected to initially drag EBITDA, with Manesar break-even estimated at 15 months.
Q3 FY25 · mediumThe greenfield facility posted an operating loss of INR 12-13 crore in Q3; any delay in reaching break-even could pressure margins.
Q3 FY25 · mediumDespite guidance, Agilus revenue growth has been sluggish (3.5% YoY) and rebranding costs may persist, delaying margin improvement.
Q3 FY25 · mediumOngoing legal cases related to the open offer and forensic audit could result in elevated legal expenses and management distraction.
Q4 FY25 · mediumThe large bed addition plan (~1,000 beds) may face ramp-up delays, with Manesar already incurring an EBITDA loss of INR 12 crore in Q4.
Q4 FY25 · mediumLegal and other legacy costs continue to consume ~1% of EBITDA, with no near-term resolution expected for the Delhi High Court case.
Q4 FY25 · mediumDespite margin improvement, Agilus revenue growth has been low single-digit; management's double-digit growth target may be challenged by competitive pressures.
Q1 FY25 · lowRecent developments in Bangladesh and Israel may affect international patient flows, though management expects no material impact.
What changed through the year
Q1 FY25 · Hospital EBITDA margin target of 20%+ for FY25
Management reiterated guidance for hospital business EBITDA margins to exceed 20% for the full year, despite Q1 margin of 18.5% impacted by one-offs and mix.
Q1 FY25 · Agilus rebranding spend of INR 50 crore in FY25
Agilus plans to spend approximately INR 50 crore on rebranding expenses this fiscal year, which will be treated as one-off costs.
Q1 FY25 · Manesar 350-bed facility to be operational in Q2 FY25
The acquired Manesar facility is expected to start operations in the ongoing quarter, initially with 100 beds, ramping up to full capacity over 18 months.
Q1 FY25 · Agilus to return to industry growth by next year
Management expects Agilus to consolidate during FY25 and return to industry-level growth in FY26, driven by brand recovery and network expansion.
Q2 FY25 · Hospital EBITDA margin expansion of 200 bps for FY25
Management reaffirmed guidance of 200 bps margin expansion for the hospital business for the full year, factoring in initial losses from Manesar.
Q2 FY25 · Agilus EBITDA margin target of 25-26% by FY27-28
Agilus aims to achieve 25-26% EBITDA margins in 15-18 months, driven by operating leverage and cost optimization.
Q2 FY25 · Brownfield bed additions of 350-400 beds in FY26
Management expects to add 350-400 beds in FY26 through brownfield expansions at Noida, FMRI, Anandapur, and BG Road.
Q2 FY25 · Capex of INR 800-900 crore per year for FY25 and FY26
Annual capex includes maintenance and growth capex for both years, supporting brownfield expansions and equipment upgrades.
Q3 FY25 · Hospital margin guidance of 20.5% for FY25
Management expects hospital EBITDA margin to reach 20.5% for the full year FY25, with a medium-term target of 25%.
Q3 FY25 · Diagnostics margin guidance of 21-22% for FY25
Agilus Diagnostics is expected to deliver adjusted EBITDA margin of 21-22% for FY25.
Q3 FY25 · Manesar greenfield to break even by Q1 FY26
The Manesar facility, currently at INR 5 crore monthly revenue, is expected to break even at INR 9 crore per month by Q1 FY26.
Q3 FY25 · Agilus to reach industry growth of 8-10% by Q2 FY26
Agilus expects to return to industry-level growth of 8-10% by Q2 FY26, driven by volume growth.
Q4 FY25 · Hospital revenue growth of 14-15% in FY26
Management expects hospital revenue to grow 14-15% in FY26, with ARPOB growth of 5-6% and volume growth making up the balance.
Q4 FY25 · Hospital EBITDA margin expansion of ~200bps in FY26
Management guided for ~200bps margin expansion in the hospital business for FY26, similar to the improvement seen in FY25.
Q4 FY25 · Agilus double-digit revenue growth and 23% EBITDA margin in FY26
Management targets double-digit revenue growth for Agilus in FY26, with EBITDA margin (net) around 23%, moving towards 25% in a couple of years.
Q4 FY25 · ~1,000 bed additions in FY26
Management plans to add approximately 1,000 beds in FY26 through brownfield expansions at Noida, Faridabad, Manesar, FMRI, and BG Road.